Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Igor Vujic

Showing results (41-50 of 57) with videos related to

Pageof 6
Sort By:
Melanoma Research|October 30, 2018
A meta-analysis of melanoma risk in industrial workersIgor Vujic, Sara Gandini, Ignazio Stanganelli, et al.
EMBO Molecular Medicine|November 9, 2024
JAK-STAT1 as therapeutic target for EGFR deficiency-associated inflammation and scarring alopeciaKaroline Strobl, Jörg Klufa, Regina Jin, et al.
Science Translational Medicine|December 13, 2019
Hair eruption initiates and commensal skin microbiota aggravate adverse events of anti-EGFR therapyJörg Klufa, Thomas Bauer, Buck Hanson, et al.
Nature Cancer|January 23, 2025
Systemic IFN-I combined with topical TLR7/8 agonists promotes distant tumor suppression by c-Jun-dependent IL-12 expression in dendritic cellsMartina Sanlorenzo, Philipp Novoszel, Igor Vujic, et al.
JAMA Dermatology|September 5, 2014
The risk of melanoma in airline pilots and cabin crew: a meta-analysisMartina Sanlorenzo, Mackenzie R Wehner, Eleni Linos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 14, 2018
BRAF and MEK Inhibitors Increase PD-1-Positive Melanoma Cells Leading to a Potential Lymphocyte-Independent Synergism with Anti-PD-1 AntibodyMartina Sanlorenzo, Igor Vujic, Arianna Floris, et al.
Biomedical Microdevices|February 6, 2015
Detection of GNAQ mutations and reduction of cell viability in uveal melanoma cells with functionalized gold nanoparticlesChristian Posch, Alfonso Latorre, Michelle B Crosby, et al.
The Journal of Investigative Dermatology|June 3, 2016
Phosphoproteomic Analyses of NRAS(G12) and NRAS(Q61) Mutant Melanocytes Reveal Increased CK2α Kinase Levels in NRAS(Q61) Mutant CellsChristian Posch, Martina Sanlorenzo, Igor Vujic, et al.
Scientific Reports|July 21, 2018
The lincRNA MIRAT binds to IQGAP1 and modulates the MAPK pathway in NRAS mutant melanomaMartina Sanlorenzo, Igor Vujic, Rosaura Esteve-Puig, et al.
Research Square|December 11, 2023
The therapeutically actionable long non-coding RNA '<i>T-RECS</i>' is essential to cancer cells' survival in NRAS/MAPK-driven melanomaValentin Feichtenschlager, Linan Chen, Yixuan James Zheng, et al.
Pageof 6

Showing results (41-50 of 57) with videos related to

Sort By:
Pageof 6
Melanoma Research|October 30, 2018
A meta-analysis of melanoma risk in industrial workersIgor Vujic, Sara Gandini, Ignazio Stanganelli, et al.
EMBO Molecular Medicine|November 9, 2024
JAK-STAT1 as therapeutic target for EGFR deficiency-associated inflammation and scarring alopeciaKaroline Strobl, Jörg Klufa, Regina Jin, et al.
Science Translational Medicine|December 13, 2019
Hair eruption initiates and commensal skin microbiota aggravate adverse events of anti-EGFR therapyJörg Klufa, Thomas Bauer, Buck Hanson, et al.
Nature Cancer|January 23, 2025
Systemic IFN-I combined with topical TLR7/8 agonists promotes distant tumor suppression by c-Jun-dependent IL-12 expression in dendritic cellsMartina Sanlorenzo, Philipp Novoszel, Igor Vujic, et al.
JAMA Dermatology|September 5, 2014
The risk of melanoma in airline pilots and cabin crew: a meta-analysisMartina Sanlorenzo, Mackenzie R Wehner, Eleni Linos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 14, 2018
BRAF and MEK Inhibitors Increase PD-1-Positive Melanoma Cells Leading to a Potential Lymphocyte-Independent Synergism with Anti-PD-1 AntibodyMartina Sanlorenzo, Igor Vujic, Arianna Floris, et al.
Biomedical Microdevices|February 6, 2015
Detection of GNAQ mutations and reduction of cell viability in uveal melanoma cells with functionalized gold nanoparticlesChristian Posch, Alfonso Latorre, Michelle B Crosby, et al.
The Journal of Investigative Dermatology|June 3, 2016
Phosphoproteomic Analyses of NRAS(G12) and NRAS(Q61) Mutant Melanocytes Reveal Increased CK2α Kinase Levels in NRAS(Q61) Mutant CellsChristian Posch, Martina Sanlorenzo, Igor Vujic, et al.
Scientific Reports|July 21, 2018
The lincRNA MIRAT binds to IQGAP1 and modulates the MAPK pathway in NRAS mutant melanomaMartina Sanlorenzo, Igor Vujic, Rosaura Esteve-Puig, et al.
Research Square|December 11, 2023
The therapeutically actionable long non-coding RNA '<i>T-RECS</i>' is essential to cancer cells' survival in NRAS/MAPK-driven melanomaValentin Feichtenschlager, Linan Chen, Yixuan James Zheng, et al.
Pageof 6